Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimized digital workflow for pathologist-grade evaluation in bleomycin-induced pulmonary fibrosis mouse model.

Scientific reports·2025
Same author

Chorein deficiency promotes ferroptosis.

FEBS open bio·2024
Same author

Association of auditory Charles Bonnet syndrome with increased blood flow in the nondominant Brodmann area 22.

PCN reports : psychiatry and clinical neurosciences·2024
Same author

Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.

Journal for immunotherapy of cancer·2024
Same author

The Role of Chorein Deficiency in Late Spermatogenesis.

Biomedicines·2024
Same author

Development of a novel artificial intelligence algorithm to detect pulmonary nodules on chest radiography.

Fukushima journal of medical science·2023
Same journal

[Basal Ganglia Circuit Mechanisms in Cognitive Learning].

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology·2018
Same journal

Experimental disease models for mechanistic understanding and drug discovery for psychiatric disorders.

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology·2018
Same journal

Experience-dependent development of visual cortical functions.

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology·2018
Same journal

The contribution of neuroplasticity induced in cholinergic neurons of the laterodorsal tegmental nucleus to cocaine addiction.

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology·2018
Same journal

[Neuroimaging studies of depression: Current status and future direction.]

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology·2018
Same journal

[Newly developed nomenclature (Neuroscience-based Nomenclature)].

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology·2016
See all related articles

Related Experiment Video

Updated: May 29, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

[Pharmacogenetics focused on special phenotypes].

Akira Sano1

  • 1Department of Psychiatry, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima 890-8520, Japan. sano@m3.kufm.kagoshima-u.ac.jp

Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology
|September 28, 2011
PubMed
Summary
This summary is machine-generated.

Parkin gene mutations in autosomal recessive juvenile Parkinsonism (ARJP) are linked to psychiatric issues and dopamine dysregulation syndrome (DDS). This suggests Parkin

More Related Videos

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Related Experiment Videos

Last Updated: May 29, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Area of Science:

  • Neuroscience
  • Genetics
  • Psychiatry

Background:

  • Autosomal recessive juvenile Parkinsonism (ARJP) results from Parkin gene mutations.
  • Patients with ARJP frequently exhibit psychiatric symptoms and dopamine dysregulation syndrome (DDS).

Purpose of the Study:

  • To explore the connection between Parkin gene dysfunction and psychiatric symptoms in ARJP.
  • To investigate the link between Parkin gene loss-of-function and the vulnerability of the reward system, potentially causing DDS.

Main Methods:

  • Review of molecular genetic studies on ARJP.
  • Analysis of clinical observations linking Parkin gene mutations to psychiatric manifestations and DDS.
  • Examination of psychotropic medication adverse effects.

Main Results:

  • Loss of function in the Parkin gene may underlie immature personality traits, leading to depression, anxiety, and suicide attempts in ARJP patients.
  • Parkin gene dysfunction appears to contribute to reward system vulnerability, manifesting as DDS.
  • The study also touches upon molecular genetic findings related to valproate-induced hyperammonemia and antipsychotic malignant syndrome.

Conclusions:

  • Parkin gene's role extends beyond motor control to influence personality and reward system function.
  • Understanding these links is crucial for managing psychiatric comorbidities in ARJP.
  • Further research into Parkin's neurobiological functions is warranted.